课题基金 / 基金详情

New Function for the Serpin PAI-2 as a Regular of pRb

New Function for the Serpin PAI-2 as a Regular of pRb
Serpin PAI-2 作为 pRb 正则的新功能
批准号:
6782721
负责人:
Toni M Antalis
金额:
$31.99万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2008-07-31

项目摘要

项目成果

Toni M Antalis的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Proteolytic cleavage of signal transduction molecules is an important mechanism for controlling cell growth, death and differentiation affecting a wide range of physiological and pathological processes. Intracellular proteolysis must be tightly regulated by endogenous inhibitors. Plasminogen activator inhibitor type 2 (PAl-2) is structurally and functionally a member of a large family of serine protease inhibitors or serpins. Serpins are key regulators of important biological processes such as complement activation, fibrinolysis, coagulation, cellular differentiation, tumor suppression, apoptosis and cell motility. PAl-2 was originally characterised as an inhibitor of the extracellular urokinase-type plasminogen activator, however PAl-2 is an inefficiently secreted serpin that exhibits a nucleocytoplasmic distribution. We have previously found that PAl-2 expression confers resistance to apoptosis and protects cells from certain cytopathic viruses in vitro. Our preliminary data identifies an intracellular activity for PAl-2 as a retinoblastoma tumor suppressor (pRb) binding protein that protects pRb from proteolytic degradation. The pRb family of proteins is ubiquitous regulators of transcription and plays a critical role in controlling cell proliferation. The central hypothesis of this application is that intracellular PAl-2 stabilizes pRb and p130, and in doing so, promotes pRb mediated activities associated with cell cycle arrest and promotion of differentiation, decreased sensitivity to E2F1 dependent apoptosis, transcriptional regulation and tumor suppression. The specific hypotheses to be tested are: 1) that PAl-2 binds pRb and the related pocket protein, p130, 2) that PAl-2 inhibits proteolytic cleavage of pRb, thereby enhancing pRb levels and pRb mediated activities, and 3) that PAl-2 promotes survival of keratinocytes and endothelial cells via pRb mediated stabilization. These hypotheses will be tested by 1) characterising the specific molecular interactions between PAl-2 and pRb utilizing mutant proteins in which specific functions have been disrupted, 2) determining the molecular mechanism by which PAl-2 stabilizes pRb and evaluating the role of calpain-like proteases in mediating proteolytic cleavage of pRb, and 3) testing the in vivo function of PAl-2 in stabilizing pRb using a PAl-2-/- mouse model. Analyses will specifically evaluate the roles of PAl-2 in keratinocyte differentiation, and endothelial cell proliferation and angiogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
  • 批准号:
    10204893
  • 项目类别:
  • 资助金额:
    $35.34万
  • 财政年份:
    2017
  • 负责人:
    Toni M Antalis
  • 依托单位:
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
  • 批准号:
    9383843
  • 项目类别:
  • 资助金额:
    $35.34万
  • 财政年份:
    2017
  • 负责人:
    Toni M Antalis
  • 依托单位:
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
  • 批准号:
    9975097
  • 项目类别:
  • 资助金额:
    $35.34万
  • 财政年份:
    2017
  • 负责人:
    Toni M Antalis
  • 依托单位:
UMB Postbaccalaureate Research Education Program
  • 批准号:
    10579976
  • 项目类别:
  • 资助金额:
    $35.78万
  • 财政年份:
    2016
  • 负责人:
    Toni M Antalis
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: